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Summary Epidermal growth factor receptor can be used as a biological marker in tumours. We examined
199 samples from 150 patients with ovarian cancer first by using a single point screen, then by full Scatchard
analysis, over a concentration range between 0.086-16.6 nM. Taking as positive those samples which showed a
20% difference between total binding and non specific binding, the EGFR was present in 39.7% of samples
ranging from 36.4% in those tumours which were classified as being mucinous to 47.7% in the undifferentiated
group. Thirty-six samples had a low affinity component (Kd> 1 nM), 27 had a high affinity component
(Kd <1 nM) and 16 had both high and low affinity components to the EGFR. There was no statistical
difference between degree ofdifferentiation of the tumour and the presence of the EGFR nor between stage of
the disease and EGFR presence.
Epidermal growth factor (EGF) interaction with EGFR
results in growth of some epithelial cancer cells in vitro and
EGFR has been found in both normal and malignant tissue
samples. Hoffmann et al. (1984) found EGFR in normal
human endometrium, while Korc et al. (1986) found the
receptor in human endometrial carcinoma. Battaglia et al.
(1989) found that 18 of 24 (75%) ovarian tumours expressed
EGFR. Bauknecht et al. (1989) reported that 64 of 151
(45%) ovarian cancers displayed the receptor. Others such as
Neal et al. (1990) found EGFR in 48% of bladder tumours.
A significant amount of work has been done with EGFR
expression in breast cancer initially by Fitzpatrick et al.
(1984), more recently by Sainsbury et al. (1985 and 1987) and
Nicholson et al. (1988). In fact Sainsbury et al. (1987) found
that both EGFR and oestrogen receptor (ER) status could
predict prognosis. Patients who were EGFR+/ER- had the
worst prognosis and those who were EGFR-/ER+ the
best.
To further investigate the role of EGFR in ovarian neo-
plasia we have examined 150 consecutive patients with
ovarian cancer who had at least one sample analysed by a
biochemical assay.
Materials and methods
Patient selection, collection and storage of tumour specimens
Patients were recruited prospectively and included any
patient with ovarian cancer. Tumour was either collected
fresh, snap frozen in liquid nitrogen and later stored at
-70°C or transported on ice in sucrose/glycerol buffer
(Crawford et al., 1984) and stored at -20'C until assayed.
Occasionally, not only one ovary but both ovaries and omen-
tum were analysed from the same patient. Experiments on
placental tissue over time and storage conditions (liquid nit-
rogen and - 70°C or sucrose/glycerol buffer and -20C)
showed that similar results were obtained (Owens, MD
thesis, 1990).
Preparation ofmembrane pellet
Tumour specimens removed from - 70'C were allowed to
thaw on ice, while those from sucrose/glycerol were re-hy-
drated in homogenising buffer (see below). The tumour speci-
men was dried with tissue paper to remove any excess water
or buffer. Specimens were washed in ice cold saline. The
tumour was bisected and two separate samples of tumour
were cut (2-3 mm minimum) from either half, one piece
placed in formal saline for pathological analysis and the
other in sucrose/glycerol buffer for later immunohistochem-
ical analysis (to be reported later). The remainder of the
tumour was used for the biochemical assay. Fresh homo-
genising buffer was prepared (20 mM Hepes, 2 mM EDTA,
0.5 mM PMSF to pH 7.4). Tumour sections were then cut
into small 1 mm blocks and weighed (usually 1 gram), then
placed in a centrifuge tube to which was added 5 ml g-' (wet
weight) of ice cold homogenising buffer. Tumour was homo-
genised on ice with an ultra turrax (Janke and Kunkel) with
2 x 15 s bursts at maximum speed but allowing the homo-
genate to cool between bursts. The homogenate was cen-
trifuged at 1,000 g for 10 min. The resulting supernatant was
centrifuged at 12,000 g for 1 h. The nuclear pellet was
resuspended in homogenising buffer and stored at - 20C
until required for DNA analysis (Modified Burton). The
pellet from the high speed spin was resuspended in 1-2 ml of
radioimmunoassay buffer (RIA buffer: 0.2 M Na2HPO4, 0.2 M
NaH2PO4, 0.1% sodium azide, 0.15 M sodium chloride, 0.1 M
EDTA and 0.5% bovine serum albumin to pH 7.4) depend-
ing on the initial wet weight (1 ml 500 mg-') and stored at
- 20C in 1.5 ml polystyrene tubes (Eppendorfs). Prior to
storage each suspension was submitted to glass teflon
homogenisation to ensure an even suspension.
Singlepoint screen
Prior to competition assays for determining the presence of
the EGFR, eppendorfs were pre-coated with RIA buffer or
phosphate buffered saline (PBS in 1% albumin) to reduce
EGF sticking to the plastic. All tumour extracts were sub-
jected to a single point screen as follows: Eppendorfs were
removed from - 20C and allowed to thaw on ice. The
membrane pellet was subjected to glass teflon homogenisa-
tion to re-establish a uniform suspension. Labelled mEGF
(1251 NEN) with a specific activity of 90-180 JCi .Lg-' was
made to a final concentration of 1 nM. The total c.p.m.'s
were about 100,000 c.p.m. 100 yI-'. The non specific binding
was determined by adding unlabelled mEGF to give 100 nM
final concentration.
To pre-coated eppendorfs was added 50ftl ofcytosol mem-
brane preparation in duplicate, plus 50 Jll of 1 nM 1251I EGF
with and without 100nM unlabelled mEGF to permit cal-
culation of specific binding. All samples were vortexed (Rota-
mixer) to ensure thorough mixing. Placental membrane was
run as a positive control. Incubation was for 2 h at room
temperature. The reaction was terminated by adding ice cold
RIA buffer (750 ld) and the eppendorfs were centrifuged at
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40,000g in a refrigerated unit at 4'C (Sarstedt) for 10min.
The supernatant was removed with a pasteur attached to a
water pump leaving a pellet which was counted on a gamma
counter (60% efficiency). The mean of each pair of results
was taken and a difference of 20% between total counts and
non specific were indicative of a positive single point screen.
When positive, a full Scatchard analysis was performed.
Scatchard analysis
Multipoint analysis was carried out at 12 points ofincreasing
concentration of labelled EGF (0.086-16.66 nM final concen-
tration). Non-specific binding was ascertained by incubating
three aliquots (501pA) of membrane preparation with the top
three concentrations of labelled EGF containing a 100-fold
excess of unlabelled EGF. Incubation and termination of the
reaction were as for the single point screen.
Data were analysed using an 'in house' programme (adap-
ted from Leake et al., 1987). The programme corrected for
non-specific binding using the three competition values (tubes
13-15). It computed the Bound and Bound/Free values. The
points were plotted with the aid of a cricket graph pro-
gramme (1.2) on an Apple Mackintosh computer. The y axis
giving the Bound/Free values and the x axis the Bound
(Total Receptor Concentration). Each line (or lines) was
computed using a minimum of five data points.
Object ofstudy
There were three main objectives in this study. Firstly to
document the incidence of EGFR in a group of 150 con-
secutive patients with ovarian cancer both by single point
screen and full Scatchard analysis. Secondly to determine if
there was any statistical difference between degree of
differentiation of the tumour and the presence of the EGFR
and finally to see if there was a difference between stage of
disease and presence of the EGFR.
Statistical analysis
Chi square testing was used for statistical analysis.
Results
Placental tissue experiments
Preliminary experiments, using a human placental membrane
fraction, were performed to find out the effect of time on the
percentage mEGF bound to placental membrane at 4°C,
room temperature and 37°C. Figure 1 shows that maximum
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binding was achieved at room temperature at 120min. This
formed the basis of the subsequent single point screens and
full Scatchard analysis. Figure 2 shows that the addition of
100 fold unlabelled mEGF to EGFR pre-filled with 125I EGF
resulted in the expected reduction in binding. This reached a
steady state (at about 20% original binding) after 2h at
room temperature.
Presence ofthe receptor
The high affinity component was taken arbitrarily when the
Kd was less than 1 nM and the low affinity component when
the Kd was equal to or greater than 1 nM.
Type oftumour andstage
The results were grouped and analysed depending on the
histological type of tumour (Serov et al., 1973) into five main
categories which comprised serous, endometrioid, mucinous,
clear cell and undifferentiated sub-types ofcommon epithelial
tumours. A further 18 patients were analysed separately. All
patients were staged in accordance with the revised FIGO
staging for ovarian cancer (Shepherd, 1989). Stage 1 and 2
were subdivided into a, b and c. However, it was not possible
to subdivide stage 3 into its various sub stages.
Results oftumour specimens
The results are divided into three tables. Table I illustrates
the patient characteristics for the major types of common
epithelial tumour. The majority of samples fall into the
serous group. Sample number is greater than patient number
because sometimes tumour was recovered from both ovaries
and omentum. The majority of patients were stage 3 and 4.
Certainly in the serous group 77.5% of patients presented
with stage 3 or 4 disease. Because it is too early to analyse
survival (follow up ranges from 1 to 19 months) it was felt
unnecessary to subdivide stage 1 and 2 at present.
Table II compares the presence of EGFR in the various
groups. EGFR presence varied between 36.4% in the muci-
nous group and 47.4% in the undifferentiated group. The
low affinity receptor was present in 31 of 73 positive samples
(42.5%), while the high affinity receptor was present in 26 of
73 (35.6%) and 16 of 73 samples (21.9%) had both high and
low affinity receptors.
Table Illa gives the various ranges and median values for
the serous, endometrioid and mucinous group with regard to
low, high and low plus high affinity receptor groups. Table
IlIb gives the results for the clear cell and undifferentiated
group.
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Figure 1 The effect of time and temperature on the percentage
of radiolabelled mEGF bound to placental membrane. 0, 37C; 0, room temp; X, 4°C.
Time (minutes)
Figure 2 Time course/temperature of displacement of labelled
mEGF by excess unlabelled EGF. 0, 4°C; 0, room temp; X,
37'C.
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Table I Patient characteristics
SER ENDO MUC CLEAR UNDIFF
Patients 80 19 11 9 13
Samples 114 20 11 14 19
Age range 25-88 43-82 45-83 52-71 43-72
Mean age 60 61.2 62.2 58.9 62.3
Number ofpatients per stage of disease
Stage I 10 9 6 1 1
Stage 2 8 2 3 1
Stage 3 41 6 2 2 6
Stage 4 21 2 3 3 5
SER: serous, ENDO: endometrioid, MUC: mucinous, CLEAR:
clear cell, UNDIFF: undifferentiated.
Table Illa EGFR characteristics
Serous Endometrioid Mucinous
Low aff Kd (nM)
(median)
(range)
TRC (fmolesmg-' DNA)
(median)
(range)
High aff Kd (nM)
(median)
(range)
TRC (fmolesmg-' DNA)
(median)
(range)
2.125 1.949
1.02-14.02 1.743-15.194 5.33 + 8.343
1398 2415
358-9645 1527-4893 977 + 1300
0.350 0.429
0.071-0.942 0.025-0.909 0.227 + 0.345
779 611
285- 1784 229-2000 984 + 1339
Table H EGFR characteristics
SER ENDO MUC CLEAR UNDIFF
Samples 114 20 11 14 19
EGFR + 46 8 4 6 9
% Pos 40.4 40 36.4 42.8 47.4
Low aff. 17 4 2 2 6
High aff. 18 3 2 1 2
High + low 11 1 3 1
SER: serous, ENDO: endometrioid, MUC: mucinous, CLEAR:
clear cell, UNDIFF: undifferentiated. EGFR +: EGFR positive, %
Pos: percentage positive, Low aff: low affinity, High aff: high affinity,
High + low: high and low affinity receptors.
Finally the results for those patients (18) which do not fall
into the five main categories are reported as follows: The
malignant mixed mesodermal group contained seven patients
(eight samples) with a mean age of 65.1 years (range 51-79
years). There was one patient with stage Ic, one with stage
2a, one stage 2b and four were stage 3. The EGFR was
present in three of eight samples (37.5%) and the receptors
were all low affinity with Kd's of 1.95 nM, 1.25 nM and
4.26 nM and with total receptor concentrations of 392, 1,107
and 20,168 fmoles mg-' DNA. The three cases (three sam-
ples) of mixed malignant epithelial tumour were all EGFR
negative. One was an endometrioid/mucinous stage Ic and
aged 60, the next was a clear cell/serous stage 4 and aged 56
and the last was a serous/mucinous aged 32 and stage ic.
There was one patient with a lipid cell tumour age 64 and
stage 3 who had a low affinity receptor (1.91 nM and TRC of
550 foles mg-' DNA). There were two endometrial stromal
sarcomas (three samples), all were EGFR negative (both
stage 3). There was one granulosa cell tumour (stage 3) in a
45 year old patient which contained the EGFR (low affinity
4.57 nM with a TRC of9,796 fmoles mg-' DNA). There were
three germ cell tumours, one a dysgerminoma (stage la)
which was EGFR negative, a malignant teratoma (stage 2b)
in a 76 year old patient which contained the high affinity
EGFR (0.412 nM and a TRC of 1,197 fmoles mg-' DNA)
and a yolk sac tumour (two samples) which was EGFR
negative (both samples). The latter was a stage 2c and the
patient was 27 years. Finally there was one patient with
unknown histology age 60, stage 3 and EGFR negative.
Statistical analysis using Chi square testing failed to show
any difference between the presence of EGFR and
differentiation or stage of disease.
Discussion
Overall EGFR was present in 39.7% of samples of ovarian
tumours. It was felt that the concentration range chosen for
the full Scatchard plots (0.086-16.6 nM) would encompass all
high and low affinity binding sites. It is difficult to compare
results with other authors such as Bauknecht et al. (1989)
who found EGFR in 45% of ovarian tumours. They used
only a single point screen for determining the receptor and if
this was positive, they assumed that receptor was therefore
present. However we were unable to confirm this point as not
High plus Low affinity receptors
Low aff Kd (nM)
(median) 6.41
(range) 2.13-17.64
TRC (fmolesmg-' DNA)
(median) 3548
(range) 1092-24667
High aff Kd
(median) 0.461
(range) 0.079-1.045
TRC (fmolesmg-' DNA)
(median) 1282
(range) 394-10563
7.45
3816
0.351
843
Low aff Kd: low affinity Kd, high aff Kd: High affinity Kd, TRC:
Total receptor concentration.
Table IIIb EGFR characteristics
Clear cell Undifferentiated
Low aff Kd (nM)
(median) 1.804
(range) 1.525 + 18.832 1.095-7.86
TRC (fmolesmg-' DNA)
(median) 787
(range) 1420 + 3801 370-3465
High aff Kd (nM)
(values)
0.175 0.533 + 0.756
TRC (values)
fmoles mg-' DNA 470 690 + 740
High plus Low affinity receptors
Low aff Kd (nM)
(median) 6.82
(range) 2.294-7.025 4.919
TRC (fmolesmg-' DNA)
(median) 2972
(range) 420-9910 6315
High aff Kd
(median) 0.145
(range) 0.056-0.531 0.75
TRC (fmolesmg-' DNA)
(median) 877
(range) 147- 1928 2263
Low aff Kd: low affinity Kd, high aff Kd: High affinity Kd, TRC:
Total receptor concentration.
all positive single point screens actually have receptors pres-
ent on full Scatchard analysis. Indeed, less than 70% of
positive single point screens contained receptor on full Scat-
chard analysis using at least five separate data points and a
regression coefficient > 0.8. We examined a number of
negative single point screen samples and were unable to
demonstrate the receptor in any case. Discordant results
occurred in up to 25% of samples when more than one
specimen from the same patient was analysed. This is prob-
ably related to the heterogeneity of ovarian tumours. Battag-
lia et al. (1989) interestingly found that 18 of 24 (75%)
primary ovarian samples expressed detectable levels of
EGFR. They only used a range of Scatchard points between
0.4-2.6 nm and this range of concentration would not neces-
sarily detect all possible high affinity components nor all low
affinity components. It is thus puzzling that Battaglia et al.910 O.J. OWENS et al.
(1989) had so many positive results. In their study metastatic
deposits had a higher concentration of EGFR compared to
primary sites and a higher median EGFR level in poorly
differentiated than in moderately and well differentiated
groups. We were unable to find any significant difference
between degree of differentiation of the tumour and the total
receptor concentration or the Kd, nor between stage of the
disease and the presence of the receptor.
The current data do not explain the significance of why
some tumours have high, some low and some both high plus
low affinity binding sites. Various mechanisms have been
proposed for the presence of two binding sites of differing
affinity. Some sites may have been occupied by endogenous
growth factors and undergone autophosphorylation and
down regulation. Dimerisation has been proposed by Schless-
inger (1988) in that monomeric receptors are in equilibrium
with oligomeric receptors. Secondly it has been shown that
there is an interaction between protein kinase C (PKC) and
the EGFR such that there is a decrease in affinity for EGF
and that high levels of PKC are associated with hormone
independent tumours (Wyss et al., 1987). Thirdly it is possi-
ble that another growth factor is interacting with PKC,
modulating EGFR (Roos et al., 1986). The observed discor-
dance in individual patients may be due to different popula-
tions of tumour cells in different sections which have been
used for biochemical assay just as there may be variations in
histology between sections.
It has been noted by Bauknecht et al. (1988) that a res-
ponse to chemotherapy occurred in 50% of EGFR positive
cancers with a mean survival time of 28 months while the
response rate in EGFR negative ovarian cancers was 12%
with a mean survival of 16 months. Our results have not yet
been analysed in this way as it was felt that the time interval
was not sufficiently long.
Currently we are therefore unable to confirm whether the
presence of the receptor (EGFR) alone has prognostic
significance and if so does high, low, or high plus low affinity
receptors have any independent functional role. It may be
that stage of the disease, degree of differentiation along with
bulk residual disease and monitoring of CA125 offer the best
prognostic indices. Secondly follow up analysis should indi-
cate whether the presence or absence of the receptor predict a
better response to chemotherapy. Finally, the significance of
discordant results require further investigation in relation to
overall tumour biology.
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